Portal de Periódicos da CAPES

Economic analysis of intermittent intravenous outpatient treatment with levosimendan in advanced heart failure in Spain

2019; Elsevier BV; Volume: 73; Issue: 5 Linguagem: Inglês

10.1016/j.rec.2019.06.020

1885-5857

Nicolás Manito Lorite, Darío Rubio-Rodríguez, José González‐Costello, C Diez Lopez, Cristina Enjuanes Grau, Javier Segovia, Juan F. Delgado, Carlos Campo, Carlos Rubio-Terrés, Josep Comín‐Colet, José Manuel García‐Pinilla, Luis Almenar‐Bonet, María G. Crespo‐Leiro, Alessandro Sionís, Teresa Blasco, Domingo A. Pascual‐Figal, Francisco González‐Vílchez, José Luis Lambert, María Grau,

Mechanical Circulatory Support Devices

Advanced heart failure (HF) leads to high hospitalization and mortality rates. The LION-HEART study was a randomized, placebo-controlled clinical trial that evaluated the safety and efficacy of intravenous administration of intermittent doses of levosimendan in outpatients with advanced HF. The aim of the present study was to perform a cost analysis to determine whether the lower rate of hospitalizations for HF, observed in patients treated with levosimendan in the LION-HEART study, can generate savings for the Spanish national health system compared with the option of not treating patients with advanced HF.An economic model was used that included IC hospitalization rates from the LION-HEART study, the costs of hospitalization due to HF and those of the acquisition and intravenous administration of levosimendan. The time horizon of the analysis was 12 months. Two analyses were carried out, one deterministic and the other probabilistic (second-order Monte Carlo simulation).In the deterministic analysis, the total saving for each patient treated with levosimendan would amount to-€698.48. In the probabilistic analysis, the saving per patient treated with levosimendan would be-€849.94 (95%CI, €133.12 to-€2,255.31). The probability of savings with levosimendan compared with the no treatment option would be 94.8%.Intermittent ambulatory treatment with levosimendan can generate savings for the Spanish national health system compared with the option of not treating patients with advanced HF.